Navigation Links
Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
Date:8/19/2007

Transaction Would Advance Company's Plan to Divest Non-Strategic Assets and

Strengthen Operating and Financial Performance

NATICK, Mass., Aug. 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced its intention to explore the sale of its Cardiac Surgery and Vascular Surgery businesses as part of the Company's plan to review its portfolio of assets and divest those considered non- strategic, and to strengthen its operating and financial performance.

"As part of an ongoing review of our assets, we have initiated a process to explore the sale of our Cardiac Surgery and Vascular Surgery businesses," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "If finalized, this sale will support our efforts to focus resources on our core businesses and improve our operating and financial performance. These are strong businesses, and we believe the combined portfolio has great potential for success with the focused attention and resources of external ownership. We are in discussions with several potential buyers, and we expect the process to take a number of months."

"This is another step in the progress we are making on our plan to divest non-strategic assets, monetize our investment portfolio and bring our expenses and head count in line with our revenues," added LaViolette. "We have now identified three non-strategic businesses to divest, and we are in discussions with potential buyers for all three. In recent months we have retained our Endosurgery group, entered into an agreement to assume sole management and control of our pain management business from Advanced Bionics and sell the Advanced Bionics auditory business, monetized parts of our portfolio, and begun developing an expense and head count reduction plan, which we plan to announce next quarter. In addition, we continue to focus on the recovery of the drug-eluting stent and cardiac rhythm management markets. Together, these measures should combine to help us achieve our overall goals of restoring profitable growth, increasing shareholder value, and continuing to build and strengthen Boston Scientific."

Boston Scientific acquired the Cardiac Surgery business in April 2006 as part of the Guidant transaction. Headquartered in San Jose with a manufacturing facility in Dorado, Puerto Rico, the Cardiac Surgery business is a leading developer of medical technologies designed to provide less-invasive therapies in cardiac surgery, including beating heart bypass surgery systems, endoscopic vessel harvesting for coronary bypass surgery, and microwave surgical ablation. The business employs approximately 450 people and had 2006 revenues of $189 million.

Boston Scientific established its Vascular Surgery business with the acquisition of Meadox Medicals in 1995. The Vascular Surgery business develops market-leading synthetic grafts and patches for repair of abdominal aortic aneurysms and peripheral vascular anatomy. The business had 2006 revenues of $86 million and has approximately 250 employees, primarily located at its manufacturing site in Wayne, New Jersey.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be a sale of any securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under applicable securities laws.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, disposition of non-strategic assets, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

617-459-2703 (mobile)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation

Copyright©2007 PR Newswire.

Related biology technology :

1. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
2. Wicab to present BrainPort at Boston conference
3. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
4. Boston entrepreneur to enliven Milwaukee angel group
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... file transfer solution that makes it easy for organizations to send and gather ... about cumbersome FTP software or email file size limitations. , Using the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Vortex Biosciences ... “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ” in ... of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the ...
(Date:5/23/2017)... ... , ... Bacterial biofilms, surface adherent communities of bacteria that are encased in ... poisoning and catheter infections to gum disease and the rejection of medical implants. ... per year, there is currently a paucity of means for preventing their formation or ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
Breaking Biology News(10 mins):